SpectronRx, a radiopharmaceutical CDMO/CMO, has secured $85.0 million in new funding from investors. This investment marks a significant milestone for the company, which specializes in the manufacturing and labeling of critical isotopes for medical applications.
SpectronRx operates as an FDA and EMA-inspected radiopharmaceutical contract development and manufacturing organization. The company is licensed to handle multiple pharmaceutical-grade Therapeutic and Diagnostic isotopes, including Pb-212, Lu-177, Ac-225, and I-131, which are vital for various clinical applications. Its quality program has been inspected by the FDA, with approved drugs such as FDG, NaF, and Ammonia. Additionally, SpectronRx provides labeling and contract manufacturing services related to Lu-177, Ac-225, I-131, I-124, In-111, Zr-89, Cu-64, and F-18. This substantial investment underscores the critical role SpectronRx plays in the rapidly evolving radiopharmaceutical sector, providing essential manufacturing and labeling services for advanced medical treatments and diagnostics. The funding round reflects investor confidence in the company's established expertise and its potential for further growth within this specialized pharmaceutical niche.
The capital raised will be used to support SpectronRx's growth initiatives, expanding its operational capabilities and advancing its specialized services. This strategic deployment of funds is intended to enable the company to meet the increasing demand for radiopharmaceuticals globally. This investment is expected to support SpectronRx's strategic expansion and reinforce its position as a key player in the radiopharmaceutical manufacturing landscape.
